ERBB2 and breast carcinoma: During treatment of Her2+ breast cancer with the anti-Her2 trastuzumab, clinical results have shown a clear correlation between treatment and impairment of the left ventricular ejection fraction (3, 4), resulting in cardiac dysfunction.